podcasts
Episode 14 – Complex assays with Ian Shoemaker, Beckman Coulter Life Sciences & Dr Oksana Sirenko, Molecular Devices
Tune in to this podcast to hear experts discuss 3D cell models, organoids and the automation of complex cell assays.
List view / Grid view
Drug Development
news
Simcere receives clearance to investigate a bi-functional fusion protein drug
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
news
Newly discovered GPCR signalling process opens possibility for novel therapies
US researchers have found that G protein-coupled receptors function in a way not previously known, which suggests untapped potential.
news
Targeting of immune cells slows cancer growth in pre-clinical studies
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
webinar
Techniques to reduce evaporation risk and cross-contamination by improving crystallisation screens
27 October 2022 | By SPT Labtech
In this webinar, you will get a practical walk-through of how to make consistent transfers from a deep well block to a crystal screening plate using an automated pipetting system and examine best practice setting up sitting-drop vapour diffusion crystallisation.
news
Incannex completes positive pre-IND meeting for traumatic brain injury candidate
Incannex Healthcare has completed a pre-IND meeting with the FDA for IHL-216A, a drug product for treatment of traumatic brain injury.
news
FDA clears Cellenkos IND application for potential ALS treatment
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
whitepaper
ebook: Current and emerging strategies for engineered cell therapies: cancer immunotherapy
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
news
China approves IND application for Everest Medicines novel BTK inhibitor
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
news
Decibel Therapeutics submits IND application for hearing loss gene therapy candidate
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.
news
Silo Pharma initiates pre-IND package for ketamine to treat fibromyalgia
Silo Pharma says it is preparing a pre-IND package and meeting with the FDA for a topical formulation of ketamine to treat fibromyalgia.
news
FDA accepts IND application for Clarametyx antibody therapy CMTX-101
Clarametyx says the FDA has accepted an IND application for first-in-human trials of CMTX-101, an antibody to treat bacterial pneumonia.
article
Drug Target Review’s highlights from ELRIG Drug Discovery 2022
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
news
Researchers have developed a drug that can break through the mucus barrier
A capsule that tunnels through mucus in the gastrointestinal tract could be used to orally administer large protein drugs such as insulin.
article
Right model, right complexity: using in vitro human disease cell models in drug discovery
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.
